KY-1044 (Alomfilimab; SAR 445256; 10 mg/kg; ip; twice a week for 3 weeks) mIgG2a (effector enable) monotherapy blocks tumor growth in lymphoma/myeloma tumor models[1].
In syngeneic mouse tumor models, KY-1044 depletes ICOShigh Treg and increases the intratumoral TEff:Treg ratio, resulting in increased secretion of IFNγ and TNFα by TEff cells[1].
| Animal Model: | 8- to 10-week-old wild-type female Balb/C or C57BL/6J mice with A20 cells[1] |
| Dosage: | 200 μg (10 mg/kg) |
| Administration: | IP; twice a week for 3 weeks starting from 6 days following tumor cell implantation |
| Result: | Triggered an antitumor response, with more than 90% of the mice being free from measurable disease at the end of the study (day 42).
|
